Exenatide QW significantly improved HbA1c reductions vs exenatide BID at 30 weeks
Authors
Drucker et al
EndoBarrier in 90 consecutively treated patients - Abstract
EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarr
Meta-analysis
Covid-19 Meta-analysis
ADA San Diego 2023 Endobarrier - Poster and Abstract
Comparing 9- vs 12-Month Implantation in the Worldwide EndoBarrier (EB) Registry
Authors:
REJ Ryder, M Yadagiri, L Munro, H Frydenberg, S Fishman, JP Byrne, JP Teare, C De Jonge, JW Greve, JJ McMaster, J Chisholm, L Kow, JC Mason, J Stein, RV Cohen, P Sen Gupta.
EASD 2023 Endobarrier 1068 patients treated worldwide - Poster
Duodenal Jejunal Bypass Liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks among 1068 patients treated worldwide.
Authors:
R.E.J. Ryder, J. Stein, T. Battelino, J. Teare, A. Ruban, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J.-W. Greve, H. Sourij, P. Sen Gupta1, K. Laubner, J. Seufert.
